CAR-T therapy's success in treating several hematological cancers has been confirmed, including some leukemias and lymphomas, but there's another condition it hopes to conquer: that of solid tumors, where it has yet to yield favorable results.
In an experiment conducted on animal subjects, scientists demonstrated that a more powerful and optimized version of CAR-T improves survival rates among rats with brain tumors, pancreatic, and lung cancers, paving the way for its potential application beyond blood cancers.
Doctor Xingxing Zang identifies the challenge in solid tumors due to a strong immunosuppressive tumor microenvironment inhibiting CAR-T efficiency and inducing CAR-T depletion in vivo.
[
add
]
[
|
|
...
]